Catalog No.
RHG37501
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Target
PLA2R, 180 kDa secretory phospholipase A2 receptor, Secretory phospholipase A2 receptor, PLA2-R, M-type receptor, C-type lectin domain family 13 member C, Soluble PLA2-R, PLA2R1, Soluble PLA2R, CLEC13C
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q13018
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA1959
The level and clinical significance of serum soluble M-type phospholipase A2 receptor in patients with primary membranous nephropathy., PMID:40462496
Fine particulate matter (PM2.5) induces microRNA-192-5p causing glomerular damage., PMID:40373708
Regulation of podocyte surface proteins by the enzyme A Disintegrin And Metalloproteinase 10 (ADAM10)., PMID:40339751
Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A2 receptor antibody: case reports., PMID:40303416
Membranous nephropathy concurrent with renal amyloidosis: a six-patient report and literature review., PMID:40260523
Nomogram for thromboembolic events in primary membranous nephropathy associated with PLA2R antibody., PMID:40234658
Construction and validation of a predictive model for malignant tumors in patients with membranous nephropathy., PMID:40121444
Case report: Coexistence of optic neuritis and primary anti-PLA2R-positive membranous nephropathy., PMID:40119269
Adverse Prognosis in Membranous Nephropathy with Phospholipase A2 Receptor 1 Epitope Spreading: A Prospective Study., PMID:40096840
Designing clinical trials for the treatment of membranous nephropathy in the anti-PLA2R era: results of a Nephcure membranous nephropathy workshop., PMID:40088237
Hypothetical Pathogenetic Model of Membranous Nephropathy., PMID:40076824
Role of PLA2R domain antibodies and epitope spreading in risk stratification and prediction of proteinuria remission in primary membranous nephropathy., PMID:40011527
Effectiveness of a Novel PLA2R1 Knock-In Rat Model in Repairing Renal Function Damage., PMID:39812124
Effectiveness of a Novel PLA2R1 Knock-in Middle Age Rat Model in Repairing Renal Function Damage., PMID:39702946
Anti Phospholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation., PMID:39698349
Prognostic value of serum complement cleavage factor Bb in idiopathic membranous nephropathy and establishment of nomogram model., PMID:39516318
A case of PLA2R-positive membranous nephropathy with subsequent development of IgG4-related disease., PMID:39514162
Updated diagnostic and therapeutic management for membranous nephropathy., PMID:39513350
Low-Dose Rituximab in the Treatment of Primary Membranous Nephropathy - A Systematic Review and Meta-Analysis., PMID:39508703
Animal models of membranous nephropathy: more choices and higher similarity., PMID:39497816
Establishment of a high-sensitivity time-resolved fluorescence immunoassay with PLA2R-IgG1 antibody and its clinical application in idiopathic membranous nephropathy prognosis., PMID:39491764
PCDH7-antibodies and PCDH7 immune deposits are mostly found in patients with PLA2R1- or NELL1-associated membranous nephropathy., PMID:39461559
Treating primary membranous nephropathy with extremely high titer of anti-phospholipase A2 receptor antibodies: A case of failed treatment with very high-dose rituximab., PMID:39292007
Efficacy and safety of rituximab in patients with PLA2R associated membranous nephropathy and resolved HCV infection., PMID:39251782
Therapeutic targets in membranous nephropathy: plasma cells and complement., PMID:39239361
The fate of immune complexes in membranous nephropathy., PMID:39185424
Clinicopathological features and outcomes of PLA2R-related membranous nephropathy with renal glycosuria., PMID:39099383
Mannose-Binding Lectin Deposition in Membranous Nephropathy and Differentiation of Primary from Secondary Forms., PMID:39062903
A single-center, open label, randomized, controlled study of hydroxychloroquine sulfate in the treatment of low risk PLA2R-associated membranous nephropathy., PMID:39030482
The Sensitivity and Specificity of Serum Phospholipase A2 Receptor Antibodies in Diagnosing Primary Membranous Nephropathy in Patients with Adult Nephrotic Syndrome and its Correlation with Serum Phospholipase A2 Receptor Staining in Kidney Biopsies., PMID:38995300
The correlation between anti-phospholipase A2 receptor antibodies and hypercoagulability in patients with idiopathic membranous nephropathy., PMID:38973428
The co-occurrence of sarcoidosis and anti-PLA2R-associated membranous nephropathy in a patient with underlying genetic susceptibility., PMID:38937663
Therapeutic plasmapheresis in idiopathic membranous nephropathy anti-PLA2R-related: A case series., PMID:38934513
Diagnosis of membranous nephropathy with Anti-GBM glomerulonephritis: a case series report., PMID:38907217
Serum Phospholipase A2 Receptor Antibody Is Associated with Thrombogenesis in Patients with Idiopathic Membranous Nephropathy., PMID:38865986
Deep analysis of total serum N-glycome suggests glyco-signatures for phospholipase A2 receptor 1-related idiopathic membranous nephropathy diagnosis., PMID:38862068
Obinutuzumab in untreated primary membranous nephropathy: An observational case series., PMID:38830643
Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study., PMID:38718066
Clinical implications of serum anti-PLA2R levels and glomerular PLA2R deposits in primary membranous nephropathy., PMID:38695230
Obinutuzumab in the treatment of PLA2R-positive membranous glomerulonephritis resistant to treatment., PMID:38631964
Combined Serologic and Genetic Risk Score and Prognostication of Phospholipase A2 receptor-Associated Membranous Nephropathy., PMID:38423528
Preference for anti-phospholipase A2 receptor antibody assay in patients with suspected membranous nephropathy: a survey study on medical practice after publication of Japanese Guidelines for Nephrotic Syndrome 2020., PMID:38402500
Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence., PMID:38312797
An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells., PMID:38309682
Lupus-like membranous nephropathy during the postpartum period expressing glomerular antigens exostosin 1/exostosin 2 and phospholipase A2 receptor: a case report., PMID:38280123
Rationale and design of the Japanese Biomarkers in Nephrotic Syndrome (J-MARINE) study., PMID:38267800
Quantity Versus Quality of Anti-Phospholipase A2 Receptor 1 Autoantibodies in the Assessment of Clinical Outcome in Membranous Nephropathy: The Debate Continues., PMID:38260930
Effectiveness of a novel rat model of off-target PLA2R1 knockout to renal impairment., PMID:38237745
Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study., PMID:38151224
THSD7A as a Promising Biomarker for Membranous Nephrosis., PMID:37884765
For research use only. Not for human or drug use.
